Wilsey Asset Management Inc. Has $23.86 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Wilsey Asset Management Inc. boosted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 6.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 941,729 shares of the biopharmaceutical company's stock after acquiring an additional 58,372 shares during the quarter. Pfizer accounts for 4.8% of Wilsey Asset Management Inc.'s portfolio, making the stock its 14th largest position. Wilsey Asset Management Inc.'s holdings in Pfizer were worth $23,863,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in PFE. Vanguard Group Inc. lifted its position in Pfizer by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company's stock worth $13,756,738,000 after buying an additional 2,285,276 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Pfizer by 19.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after buying an additional 25,315,159 shares in the last quarter. Geode Capital Management LLC lifted its position in Pfizer by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company's stock worth $3,190,131,000 after buying an additional 2,923,537 shares in the last quarter. Norges Bank bought a new stake in Pfizer during the 4th quarter worth about $2,328,986,000. Finally, Massachusetts Financial Services Co. MA lifted its position in Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after buying an additional 5,350,381 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of PFE traded down $0.33 during mid-day trading on Friday, hitting $24.51. 46,354,360 shares of the company's stock were exchanged, compared to its average volume of 41,209,115. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The stock's 50-day simple moving average is $23.06 and its 200-day simple moving average is $24.95. The firm has a market cap of $139.35 billion, a price-to-earnings ratio of 17.38, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same period last year, the firm earned $0.82 earnings per share. The business's revenue for the quarter was down 7.8% on a year-over-year basis. On average, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.02%. Pfizer's dividend payout ratio is 124.64%.

Analyst Ratings Changes

PFE has been the topic of several analyst reports. Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. UBS Group upped their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, Cantor Fitzgerald initiated coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.